TriGemX Bio (formerly Kallyope) is a New York City-based biotechnology company developing medicines for the treatment of migraine by leveraging insights into neural signaling pathways. Its lead program, elismetrep, is a novel oral TRPM8 channel blocker in Phase 3 trials for the acute treatment of migraine, with results from the first Phase 3 trial anticipated in mid-2027. The company name references the trigeminal ganglion, a migraine-relevant neural structure where TRPM8 is expressed.
1
Round
1
Industry
5
Tags
Oct 1, 2026
Latest raise
Funding activity · 1 round
Oct 1, 2026
$94M
Series C+
Led by The Column Group
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
